|26th August 2020||Lindsay A Md Rosenwald||52,500||Open or private purchase||$18.00||$945,000.00|
|14th July 2020||Michael S Weiss||16,611||Grant/award etc.||$0.00|
|14th July 2020||Adam J. Chill||16,611||Grant/award etc.||$0.00|
|14th July 2020||Neil Herskowitz||16,611||Grant/award etc.||$0.00|
|14th July 2020||Lindsay A Md Rosenwald||16,611||Grant/award etc.||$0.00|
|14th July 2020||Michael J Zelefsky||16,611||Grant/award etc.||$0.00|
|22nd June 2020||Michael S Weiss||1,556,029||Grant/award etc.||$0.00|
|16th June 2020||Neil Herskowitz||10,000||Grant/award etc.||$0.00|
|11th June 2020||Manuel Md Litchman||153,846||Open or private purchase||$3.25||$499,999.50|
|5th June 2020||Neil Herskowitz||24,390||Grant/award etc.||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID. The company was founded on March 13, 2015 and is headquartered in New York, NY.